Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%

NCT04547504 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04547504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04547504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%
Lead sponsor
University Hospital, Brest
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 22, 2020
Completion date
December 22, 2025
Enrollment
349 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer